Apimeds Pharmaceuticals US, Inc. (APUS) stock
APUSNYSEPharmaceutical PreparationsFiscal year ends December 31
$1.95−0.09 (-4.41%)
Close on Nov 17, 2026Market cap $2.94MP/E –Yield –
Apimeds Pharmaceuticals US revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $2.90M | – |
| Q2 FY2026 | Jun 30, 2026 | $282.73K | – |
See a number that looks wrong?